WEKO3
アイテム
Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy
https://repo.qst.go.jp/records/49373
https://repo.qst.go.jp/records/49373dd8788b7-26de-49cb-a825-d08af4124b25
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-12-28 | |||||
| タイトル | ||||||
| タイトル | Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kasuya, Goro
× Kasuya, Goro× Ishikawa, Hitoshi× Tsuji, Hiroshi× Haruyama, Yasuo× Kobashi, Gen× Ebner, Daniel× Akakura, Kouichirou× Suzuki, Hiroyoshi× Tomohiko, Ichikawa× Shimazaki, Jun× Makishima, Hirokazu× Nomiya, Takuma× Kamada, Tadashi× Tsujii, Hirohiko× 粕谷 吾朗× 石川 仁× 辻 比呂志× 春山 康夫× 小橋 元× エブナー ダニエル× 赤倉 功一郎× 市川 智彦× 島崎 淳× 牧島 弘和× 野宮 琢磨× 鎌田 正× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The treatment outcomes of patients with high-risk localized prostate cancer (PC) after carbon-ion radiotherapy (CIRT) combined with long-term androgen deprivation therapy (LTADT) were analyzed, and compared with those of other treatment modalities, focusing on PC-specific mortality (PCSM). A total of 1247 patients were enrolled in three phase II clinical trials of fixed-dose CIRT between 2000 and 2013. Excluding patients with T4 disease, 608 patients with high- or very-high-risk PC, according to the National Comprehensive Cancer Network classification system, who received CIRT with LTADT were evaluated. The median follow-up was 88.4 months, and the 5-/10-year PCSM rates were 1.5%/4.3%, respectively. T3b disease, Gleason score of 9-10, and percentage of positive biopsy cores > 75% were associated with significantly higher PCSM on univariate and multivariate analyses. The 10-year PCSM rates of patients having all three (n=16), two (n=74), or one of these risk factors (n=217) were 27.1%, 11.6%, and 5.7%, respectively. Of the 301 patients with none of these factors, only 1 PCSM occurred over the 10-year follow-up (10-year PCSM rate, 0.3%), and significant differences were observed among the four stratified groups (p < 0.001). CIRT combined with LTADT yielded relatively favorable treatment outcomes in patients with high-risk PC and very favorable results in patients without any of the three abovementioned factors for PCSM. Because a significant difference in PCSM among the high-risk PC patient groups was observed, new categorization and treatment intensity adjustment may be required for high-risk PC patients treated with CIRT. This article is protected by copyright. All rights reserved. | |||||
| 書誌情報 |
Cancer science 巻 108, 号 12, p. 2422-2429, 発行日 2017-12 |
|||||
| 出版者 | ||||||
| 出版者 | Wiley Publishing on behalf of the Japanese Cancer Association | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1347-9032 | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 28921785 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1111/cas.13402 | |||||
